Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (8): 908-918.doi: 10.12092/j.issn.1009-2501.2022.08.010

Previous Articles     Next Articles

Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease

MA Shen1,2,3,4, LIU Yushuo1,2,3,4, TANG Hui5, CHEN Wenbin6, GAO Ling1,2,3,4,6   

  1. 1Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
  • Received:2022-01-21 Revised:2022-03-13 Online:2022-08-26 Published:2022-09-13

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in China. There is no specific drug approved for marketing at home and abroad. At present, some adjuvant drugs are mainly used to improve the progress of the disease. Being familiar with and mastering the pharmacokinetic characteristics is very important for the selection and use of drugs. According to the characteristics of drug absorption, distribution, metabolism and excretion, reasonable drugs are selected to improve the therapeutic effect and reduce adverse reactions. Therefore, this paper reviews the pharmacokinetics and clinical significance of drugs commonly used to improve nonalcoholic fatty liver disease in hope of providing basis for clinical medication.

Key words: nonalcoholic fatty liver disease, drug, pharmacokinetics, clinical significance

CLC Number: